Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1961 3
1962 1
1963 6
1964 59
1965 1172
1966 1547
1967 1658
1968 1917
1969 2073
1970 2210
1971 2204
1972 2562
1973 2937
1974 3269
1975 3843
1976 4128
1977 4107
1978 4528
1979 4390
1980 4371
1981 4917
1982 5342
1983 6125
1984 6252
1985 7101
1986 7828
1987 8361
1988 8807
1989 10542
1990 11727
1991 12068
1992 12027
1993 12558
1994 18843
1995 20535
1996 19768
1997 21385
1998 21858
1999 23501
2000 22467
2001 21377
2002 22004
2003 25138
2004 27901
2005 30591
2006 30071
2007 31247
2008 30659
2009 31420
2010 33484
2011 37815
2012 41201
2013 44062
2014 43338
2015 41594
2016 39111
2017 38400
2018 37335
2019 37405
2020 37568
2021 37979
2022 34868
2023 28887
2024 4138

Text availability

Article attribute

Article type

Publication date

Search Results

25,681 results

Results by year

Filters applied: Clinical Trial, in the last 1 year. Clear all
Page 1
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.
Leroux-Roels I, Davis MG, Steenackers K, Essink B, Vandermeulen C, Fogarty C, Andrews CP, Kerwin E, David MP, Fissette L, Vanden Abeele C, Collete D, de Heusch M, Salaun B, De Schrevel N, Koch J, Verheust C, Dezutter N, Struyf F, Mesaros N, Tica J, Hulstrøm V. Leroux-Roels I, et al. J Infect Dis. 2023 Mar 28;227(6):761-772. doi: 10.1093/infdis/jiac327. J Infect Dis. 2023. PMID: 35904987 Free PMC article. Clinical Trial.
Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery.
Morimoto S, Takahashi S, Ito D, Daté Y, Okada K, Kato C, Nakamura S, Ozawa F, Chyi CM, Nishiyama A, Suzuki N, Fujimori K, Kondo T, Takao M, Hirai M, Kabe Y, Suematsu M, Jinzaki M, Aoki M, Fujiki Y, Sato Y, Suzuki N, Nakahara J; Pooled Resource Open-Access ALS Clinical Trials Consortium; Okano H. Morimoto S, et al. Cell Stem Cell. 2023 Jun 1;30(6):766-780.e9. doi: 10.1016/j.stem.2023.04.017. Cell Stem Cell. 2023. PMID: 37267913 Free article. Clinical Trial.
Bacterial Decolonization for Prevention of Radiation Dermatitis: A Randomized Clinical Trial.
Kost Y, Deutsch A, Mieczkowska K, Nazarian R, Muskat A, Hosgood HD, Lin J, Daily JP, Ohri N, Kabarriti R, Shinoda K, McLellan BN. Kost Y, et al. JAMA Oncol. 2023 Jul 1;9(7):940-945. doi: 10.1001/jamaoncol.2023.0444. JAMA Oncol. 2023. PMID: 37140904 Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: This phase 2/3 randomized clinical trial was conducted from June 2019 to August 2021 with investigator blinding at an urban academic cancer center and enrolled patients with breast cancer or head and neck cancer receiving radiation …
DESIGN, SETTING, AND PARTICIPANTS: This phase 2/3 randomized clinical trial was conducted from June 2019 to August 2021 with i …
Nasal Iodophor Antiseptic vs Nasal Mupirocin Antibiotic in the Setting of Chlorhexidine Bathing to Prevent Infections in Adult ICUs: A Randomized Clinical Trial.
Huang SS, Septimus EJ, Kleinman K, Heim LT, Moody JA, Avery TR, McLean L, Rashid S, Haffenreffer K, Shimelman L, Staub-Juergens W, Spencer-Smith C, Sljivo S, Rosen E, Poland RE, Coady MH, Lee CH, Blanchard EJ, Reddish K, Hayden MK, Weinstein RA, Carver B, Smith K, Hickok J, Lolans K, Khan N, Sturdevant SG, Reddy SC, Jernigan JA, Sands KE, Perlin JB, Platt R. Huang SS, et al. JAMA. 2023 Oct 10;330(14):1337-1347. doi: 10.1001/jama.2023.17219. JAMA. 2023. PMID: 37815567 Clinical Trial.
First-in-human clinical trial of allogeneic, platelet-derived extracellular vesicles as a potential therapeutic for delayed wound healing.
Johnson J, Law SQK, Shojaee M, Hall AS, Bhuiyan S, Lim MBL, Silva A, Kong KJW, Schoppet M, Blyth C, Ranasinghe HN, Sejic N, Chuei MJ, Tatford OC, Cifuentes-Rius A, James PF, Tester A, Dixon I, Lichtfuss G. Johnson J, et al. J Extracell Vesicles. 2023 Jul;12(7):e12332. doi: 10.1002/jev2.12332. J Extracell Vesicles. 2023. PMID: 37353884 Free PMC article. Clinical Trial.
In a first-in-human, double-blind, placebo-controlled, phase I clinical trial of healthy volunteer adults, designed primarily to assess safety in the context of wound healing, we demonstrate that injections of LEAP-purified pEVs in formulation buffer are safe and we …
In a first-in-human, double-blind, placebo-controlled, phase I clinical trial of healthy volunteer adults, designed primarily …
Patient-Centered Clinical Trial Design for Heart Failure Devices via Bayesian Decision Analysis.
Chaudhuri SE, Adamson P, Bruhn-Ding D, Ben Chaouch Z, Gebben D, Rincon-Gonzalez L, Liden B, Reed SD, Saha A, Schaber D, Stein K, Tarver ME, Lo AW. Chaudhuri SE, et al. Patient. 2023 Jul;16(4):359-369. doi: 10.1007/s40271-023-00623-0. Epub 2023 Apr 19. Patient. 2023. PMID: 37076697 Clinical Trial.
BACKGROUND: The statistical significance of clinical trial outcomes is generally interpreted quantitatively according to the same threshold of 2.5% (in one-sided tests) to control the false-positive rate or type I error, regardless of the burden of disease or patien …
BACKGROUND: The statistical significance of clinical trial outcomes is generally interpreted quantitatively according to the s …
Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.
Garcia-Donas J, Martínez-Urbistondo D, Velázquez Kennedy K, Villares P, Barquin A, Dominguez A, Rodriguez-Moreno JF, Caro E, Suarez Del Villar R, Nistal-Villan E, Yagüe M, Ortiz M, Barba M, Ruiz-Llorente S, Quiralte M, Zanin M, Rodríguez C, Navarro P, Berraondo P, Madurga R. Garcia-Donas J, et al. Front Immunol. 2023 Apr 18;14:1156603. doi: 10.3389/fimmu.2023.1156603. eCollection 2023. Front Immunol. 2023. PMID: 37143685 Free PMC article. Clinical Trial.
Cytokine profiles could identify cases at risk of severe disease. METHODS: We designed a randomized phase II clinical trial to determine whether the combination of ruxolitinib (5 mg twice a day for 7 days followed by 10 mg BID for 7 days) plus simvastatin (40 mg onc …
Cytokine profiles could identify cases at risk of severe disease. METHODS: We designed a randomized phase II clinical trial to …
A multicenter randomized, controlled clinical trial of adjuvant sintilimab for esophageal squamous cell carcinoma.
Sun HB, Xing WQ, Liu XB, Yang SJ, Chen PN, Liu SL, Li P, Ma YX, Jiang D, Yan S. Sun HB, et al. Future Oncol. 2023 Aug;19(26):1777-1784. doi: 10.2217/fon-2022-1255. Epub 2023 Sep 22. Future Oncol. 2023. PMID: 37737025 Clinical Trial.
The results of this randomized controlled trial addressed controversy regarding the survival benefits of adjuvant sintilimab treatment for patients with resected locally advanced ESCC. Clinical Trial Registration: NCT05495152 (ClinicalTrials.gov)....
The results of this randomized controlled trial addressed controversy regarding the survival benefits of adjuvant sintilimab treatment for p …
25,681 results
You have reached the last available page of results. Please see the User Guide for more information.